4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-25-015787
CHIEF SCIENTIFIC OFFICER sold 7,500 shares at $20.03 ($150,220)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER
Table I: Non-derivative
1 line| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2025-06-03 | Sale : show line 1 in the form 10b5-1 | −7,500 | $20.03 | $150,220 | 977,688 | I |
| Open-market sales · 7,500 sh · avg $20.03 · $150,220 | ||||||
Loading xslF345X05/form4-06052025_080654.xml…